• Novartis hits targets in late-stage QMF149 asthma trial pharmatimes
    June 05, 2019
    Novartis has announced that a phase III QUARTZ study of its investigational inhaled combination treatment, QMF149, has met primary and key secondary endpoints in patients with inadequately controlled asthma.
PharmaSources Customer Service